Business Description
Celgene Corp
NAICS : 325412
SIC : 2834
ISIN : ARBCOM4601B6
Share Class Description:
BUE:CELG: CedearDescription
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.55 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.64 | |||||
Debt-to-EBITDA | 2.45 | |||||
Interest Coverage | 10.58 | |||||
Piotroski F-Score | 8/9 | |||||
Beneish M-Score | -2.53 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.5 | |||||
3-Year EBITDA Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 27.1 | |||||
3-Year Book Growth Rate | 1.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.89 | |||||
Quick Ratio | 2.8 | |||||
Days Inventory | 270.69 | |||||
Days Sales Outstanding | 51.03 | |||||
Days Payable | 245.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 96.31 | |||||
Operating Margin % | 47.6 | |||||
Net Margin % | 34.62 | |||||
ROE % | 71.15 | |||||
ROA % | 15.65 | |||||
ROIC % | 26.07 | |||||
ROC (Joel Greenblatt) % | 516.75 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 8.8 | |||||
Shiller PE Ratio | 86.77 | |||||
Price-to-Owner-Earnings | 12.64 | |||||
PS Ratio | 4.83 | |||||
PB Ratio | 6.78 | |||||
Price-to-Free-Cash-Flow | 10.99 | |||||
Price-to-Operating-Cash-Flow | 10.05 | |||||
EV-to-EBIT | 1.2 | |||||
EV-to-EBITDA | 1.1 | |||||
EV-to-Revenue | 0.52 | |||||
Earnings Yield (Greenblatt) % | 83.33 | |||||
Forward Rate of Return (Yacktman) % | 25.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celgene Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | |||
| EPS (TTM) (ARS) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (ARS) | - | ||
| 20-Day SMA (ARS) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (ARS) | 0 - 0 | ||
| Shares Outstanding (Mil) | 700.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celgene Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celgene Corp Stock Events
| Event | Date | Price (ARS) | ||
|---|---|---|---|---|
| No Event Data | ||||
Celgene Corp Frequently Asked Questions
What is Celgene Corp(BUE:CELG)'s stock price today?
The current price of BUE:CELG is ARS0.00. The 52 week high of BUE:CELG is ARS0.00 and 52 week low is ARS0.00.
When is next earnings date of Celgene Corp(BUE:CELG)?
The next earnings date of Celgene Corp(BUE:CELG) is .
Does Celgene Corp(BUE:CELG) pay dividends? If so, how much?
Celgene Corp(BUE:CELG) does not pay dividend.
Press Release
Articles on Celgene Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers